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Abstract 
 
Purpose 
A phase III study adding aprepitant to a 5HTT3 receptor antagonist plus dexamethasone in germ 
cell tumor (GCT) patients treated with 5 day cisplatin combination chemotherapy demonstrated a 
significant improvement in complete response (CR) (J Clin Onc 30:3998-4003, 2012). 
Fosaprepitant has demonstrated non-inferiority compared to aprepitant in single day cisplatin 
chemotherapy and is approved as a single-dose alternative. This single arm phase II study is the 
first clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin regimen. 
Methods 
GCT patients receiving 5 day cisplatin combination chemotherapy were enrolled. Fosaprepitant 
150 mg was given IV on days 3 and 5. A 5HT3 antagonist days 1-5 (days 1, 3, 5, if palonosetron) 
plus dexamethasone 20 mg days 1, 2, and 4 mg po bid days 6, 7, 8 was administered. Rescue 
antiemetics were allowed. The primary objective was to determine the CR rate – no emetic 
episodes or use of rescue medications. Accrual of 64 patients was planned with expected CR>27%.  
Results  
65 patients were enrolled of whom 54 were eligible for analysis. Median age was 33. 51 patients 
received BEP (bleomycin, etoposide, cisplatin) chemotherapy. CR was observed in 13 (24.1%) 
patients (95% Agresti-Coull binomial C.I. 14.5%, 37.1%). 
Conclusion 
The data in this phase II study, in contrast to our prior phase III study, appears to indicate a lower 
CR rate with the substitution of fosaprepitant for aprepitant. It is unknown whether the 
substitution of fosaprepitant for aprepitant provides the same benefit in multi-day cisplatin that 
was achieved with single day cisplatin.  
 
-Keywords: germ cell tumor, testicular cancer, fosaprepitant, chemotherapy-induced nausea and 
vomiting  
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Introduction 
 
Germ-cell tumors (GCTs) represent the most common carcinoma in men ages 15 to 35 years. 
There is an estimated 8,430 new cases to be diagnosed in the United States in 2015 [1]. The 
introduction of cisplatin-based combination chemotherapy has established testicular cancer as a 
model for a curable neoplasm [2]. Acute and delayed nausea and vomiting is a universal adverse 
effect of cisplatin chemotherapy. Despite significant progress in the prevention of chemotherapy-
induced nausea and vomiting (CINV), emesis continues to be associated with a significant 
deterioration in quality of life in patients treated with combination chemotherapy [3]. The 
addition of the brain-penetrant neurokinin-1 receptor antagonist (NK1-RA) aprepitant, to a 5-
hydroxytryptamine-3 receptor antagonist (5HT3-RA) and dexamethasone improved the 
prevention of CINV in patients receiving highly emetogenic single-day cisplatin chemotherapy 
[4-6]. In the Hoosier Cancer Research Network (HCRN), a phase III study was conducted with a 
5HT3-RA plus dexamethasone plus either aprepitant or placebo in a randomized double-blind 
placebo controlled study of patients receiving 5 day cisplatin-based combination chemotherapy. 
This study demonstrated a significant improvement in complete response (CR) rate of 42% 
versus 13% (P<0.001) favoring aprepitant [7].  
Although the oral capsule is appropriate for many patients, the availability of an intravenous (IV) 
formulation would provide further convenience and flexibility. Fosaprepitant is a water-soluble 
prodrug of aprepitant available in IV formulation. It is rapidly converted to the active form 
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(aprepitant) by phosphatase enzymes and is expected to provide the same aprepitant exposure in 
regards to AUC and hence similar antiemetic effect [8].  
A randomized, double-blind phase III study was conducted to assess the efficacy and safety of 
fosaprepitant in the prevention of CINV in cisplatin-naive patients who were treated with 
chemotherapy regimens that included single-day cisplatin ≥ 70 mg/m2 [9] enrolled over 2,200 
patients and demonstrated that a single dose of intravenous fosaprepitant was non-inferior to 
standard 3-day oral aprepitant. Here we report the results of the first clinical trial evaluating 
fosaprepitant in patients receiving multi-day cisplatin combination chemotherapy.  
 
Methods 
 
Patient Selection 
Eligible patients were ≥ 15 years of age with histologically or cytologically confirmed diagnosis 
of germ cell tumor who were scheduled to receive a standard 5 day cisplatin based chemotherapy 
regimen. Prior chemotherapy was allowed and patients did not have to be chemotherapy naive. 
Patients had to be without nausea or vomiting for 24 hours before study entry and no antiemetic 
use for 72 hours prior to starting protocol therapy. Absolute neutrophil count ≥ 1,500 cells/µL, 
WBC count ≥ 3,000 cells/µL, platelet count ≥ 100,000 cells/µL, AST and ALT ≤ 3 x upper limit 
of normal, bilirubin ≤ 1.5 x upper limit of normal, and creatinine less than 2 mg/dL were required. 
Patients should have had an ECOG performance status of 0-2 and no active central nervous system 
(CNS) metastasis.  
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This single arm HCRN phase II study was conducted from 2013 to 2015 after approval by each 
site’s institutional review board. Informed consent was obtained from all individual participants 
included in the study.   
Study design and treatment regimen 
All participating patients received germ cell combination chemotherapy utilizing cisplatin 
20mg/m2 x 5 days. All patients received an anti-emetic regimen consisting of dexamethasone 
20mg orally daily on days 1 and 2 then 4mg orally BID (twice daily) on days 6, 7, and 8. A 5HT3-
RA was administered to all patients 30 minutes before starting chemotherapy: ondansetron 8mg 
orally BID on days 1 to 5 or palonosetron 0.25mg IV on days 1, 3, and 5. Fosaprepitant 150mg 
was administered IV on days 3 and 5 over 20-30 minutes (Table 1). Patients were permitted to take 
rescue therapy of the treating investigator’s choice for nausea and/or emesis/retching based on 
clinical circumstances. No additional doses of 5HT3-RA, dexamethasone, or fosaprepitant were 
given during the acute or delayed treatment periods. Patients who required rescue therapy were 
permitted to continue the study at the discretion of the treating investigator and in consultation 
with the patient.  
The primary endpoint was complete response (CR) of both acute (days 1 through 5) and delayed 
(days 6 through 8) CINV, defined by no emetic episodes or use of rescue medications. Secondary 
endpoints included incidence of emetic episodes via patients logs (days 1 through 8), use of rescue 
medications (days 1 through 8), patient’s self-reported assessment of nausea (days 1 through 8) 
using a 0-100mm visual analog scale (VAS), safety, and toxicity.     
Study visits and assessment procedures 
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In the pre-study period, all pertinent demographics (age, gender, height, and weight) and medical 
data (site and stage of disease, ECOG performance status, laboratory values, medications, and 
prior oncologic therapies) were recorded.  
All patients were provided a diary inclusive of days 1 through 8 of the chemotherapy cycle. 
Patients were asked to complete a daily log of any episodes of vomiting or retching and the time 
of these episodes beginning with day 1 and daily through day 8. The use of rescue therapy, defined 
as any medication taken to treat established nausea or emesis, was also recorded. On days 1 through 
8, patients rated nausea by using a 100-mm horizontal VAS ranking their nausea for the prior 24 
hours from no nausea to the worst nausea with a measurement of 0-100mm. A VAS score of 0 to 
5mm was considered as no nausea.  
Statistical Methods 
The CR rate of aprepitant in GCT patients receiving 5 day cisplatin-based combination 
chemotherapy was 42% [7]. We expected fosaprepitant to have similar CR rate. A one-sided score 
test was used to compare the CR rate of fosaprepitant with the historical data of aprepitant. 
Denoting the CR rate of fosaprepitant as p, the hypotheses are H0: p ≤ 27% versus HA: p ≥ 27%. 
A CR rate of fosaprepitant that is no worse than 15% lower than aprepitant was considered worth 
further investigation. Enrollment of 64 patients was required to attain a power of 0.80 with type I 
error level as 0.05. 
Continuous variables were summarized by mean, median, and range. Categorical variables were 
summarized by frequencies and percentages. Overall CR was tested according to the 
aforementioned hypotheses. In addition, 95% confidence interval of Agresti-Coull type was 
constructed for the overall CR. Adverse events were summarized by their grades and types. 
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Results 
 
Patient characteristics  
From January 2013 till May 2015, patients with GCT who were scheduled to receive 5 day 
cisplatin chemotherapy were enrolled. A total of 65 patients were enrolled on study. One patient 
had a reaction to the infusion and was taken off study. 10 patients were not evaluable because 
they did not complete the VAS on all 8 days. Hence, 54 patients were evaluable and eligible for 
analysis Demographic and treatment data are listed in Table 1. Median age was 33 (range 15-66). 
All patients were Caucasian and male. Eastern Cooperative Oncology Group (ECCOG) 
Performance Status was 0 in 59 (92.2%) patients, 1 in 4 (6.2%) patients, and 2 in 1 (1.6%) 
patient. Chemotherapy regimen consisted of BEP (bleomycin, etoposide, cisplatin) in 51 (79.7%) 
patients, EP (etoposide, cisplatin) in 10 (15.6%) patients, VeIP (vinblastine, ifosfamide, 
cisplatin) in 2 (3.1%) patients, and cisplatin/epirubicin in 1 (1.6%) patient. All evaluable patients 
received fosaprepitant 150mg IV on days 3 and 5. Among evaluable patients, 4 received 
ondansetron and and 50 received palonosetron. All evaluable patient received 5 days of 
dexamethasone. Among evaluable patients, 50 (92.6%) were chemotherapy-naïve. Table 2 
depicts patient and treatment characteristics.    
Efficacy Endpoints 
Primary and secondary endpoints were analyzed in the 54 evaluable patients. Complete response 
(CR), defined by no emetic episodes and no use of rescue medications, was observed in 13 
(24.1%) patients in the overall treatment period day 1-8 (95% Agresti-Coull binomial C.I. 
14.5%, 37.1%). This was insufficient to reject the null hypothesis H0: p ≤ 27% (p=0.68). CR was 
observed in 16 (29.6%) patients during the acute phase (days 1 through 5) and 25 (46.3%) 
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patients in the delayed phase (days 6 through 8). Figure 1 depicts the percentage of CR in the 
acute, delayed, and overall phases. Sixteen (29.6%) patients had at least one emetic episode. 
Total number of emetic episodes was 29. Nine patients had 1 emetic episode; 2 patients had 2 
episodes; 4 patients and 3 episodes and 1 patient had 4 emetic episodes. The largest number of 
emetic episodes occurred on days 3, 5, and 7 with 5 patients having an emetic episode on each of 
these days. The fewest number of emetic episodes occurred on days 1 and 6 with 2 patients 
having an emetic episode on these days. Figure 2 depicts a histogram indicating the percentage 
of patients who had emetic episodes on days 1 through 8.  Thirty-seven (68.5%) patients 
received rescue medications. Rescue medications consisted of Lorazepam, Prochlorperazine, 
Promethazine, or Dexamethasone. Lorazepam was the most common rescue medication used. 
There were 225 episodes in 47 patients of reported nausea >5mm on the VAS in the 8 day 
reporting period. Figure 3 depicts the median VAS score on days 1 through 8.  No patient had a 
change in their planned cisplatin-based combination chemotherapy schedule. 
 
 
Safety 
Sixty-four patients were evaluable for toxicity. Administration of fosaprepitant was well 
tolerated. There was a total of 7 grade III or IV toxicity events on this study that were possibly, 
probably, or definitely related to study drug. Two patients had grade III toxicity consisting of 
leukopenia and thrombocytopenia. Four patients had grade IV toxicity consisting of leukopenia 
and neutropenia. One patient had grade IV toxicity consisting of febrile neutropenia. There was 
no cases of reaction at the infusion site attributable to fosaprepitant infusion on this study. 
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Discussion 
 
Severe CINV were common adverse events associated with certain chemotherapeutic regimens 
and forced a substantial number of patients to delay or even refuse potentially curative therapy 
[10]. Despite the compelling advances made in recent years, CINV continues to be among the 
most distressing and feared adverse effects of chemotherapy [11].  Prior to the introduction of 
ondansetron, the first 5HT3 receptor antagonist, the typical patient with testicular cancer would 
experience a median of 10 emetic episodes on day 1 of a 5 day cisplatin-based chemotherapy 
course, 5 episodes on day 2, and decreasing emetic episodes on later days [12]. The introduction 
of ondansetron was fundamental in preventing acute nausea and vomiting associated with 
cisplatin-based chemotherapy [13,14]. More recently, this trend has been reversed in multi-day 
cisplatin as patients experience more severe symptoms of CINV on later days of the 
chemotherapy cycle (days 3-5) as well as delayed CINV on days 6-8 [15].  
The addition of dexamethasone in phase III studies resulted in further improvement in the 
prevention of acute CINV [16]. Delayed CINV was not adequately controlled by 5HT3 receptor 
antagonists and dexamethasone [17].  
Aprepitant, a NK1-RA, demonstrated efficacy in controlling both acute and delayed CINV and 
hence it was combined with previous antiemetic regimens. Aprepitant was initially given for 5 
days [18] but eventually a 3 day course was deemed sufficient [6]. Aprepitant proved to be 
efficacious in preventing CINV in a randomized double-blind placebo-controlled trial which 
enrolled cisplatin-naïve patients who were treated with chemotherapy regimens including 
cisplatin ≥ 70 mg/m2 administered on a single day [6]. In the HCRN, a phase III study was 
conducted to test the efficacy of aprepitant in patients undergoing a 5-day cisplatin-based 
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combination chemotherapy regimen [7]. In this randomized double-blind placebo-controlled 
crossover study, 42% of patients achieved a CR, defined as no emetic episodes and no use of 
rescue medications, with aprepitant compared to 13% with placebo (p < 0.001).  
An intravenous formulation of a NK1-RA was developed. Fosaprepitant is a water-soluble 
phosphoryl prodrug of aprepitant which when administered intravenously, rapidly converts to 
aprepitant within 30 minutes of administration [19]. A phase III trial compared single dose 
fosaprepitant 150mg IV in combination with granisetron 40 µg/kg IV and dexamethasone to a 
control regimen of placebo, granisetron, and dexamethasone [20]. Complete response, defined by 
no emesis and no rescue therapy, was higher in the fosaprepitant arm than in control arm; 64% 
vs. 47% (p = 0.0015). Fosaprepitant was more effective than control regimen in both acute and 
delayed phases. A phase III randomized, double-blind, non-inferiority study was conducted 
comparing fosaprepitant to aprepitant in chemotherapy-naïve patients receiving cisplatin ≥ 70 
mg/m2 [9]. A single dose of intravenous fosaprepitant was shown to be non-inferior to standard 
3-day oral aprepitant in preventing CINV in patients receiving single-day cisplatin. However, 
there is a paucity of data with fosaprepitant in patients receiving a 5-day cisplatin combination 
chemotherapy regimen. 
The HCRN conducted this single arm phase II study as a first evaluation of fosaprepitant in 
patients receiving 5-day cisplatin-based combination chemotherapy for GCT. We have used 
dexamethasone only on days 1 and 2 of the acute phase in an attempt to decrease the adverse 
effects of corticosteroids. Patients with GCT who are receiving three to four cycles of cisplatin 
combination chemotherapy will be subjected to high doses of dexamethasone which will put 
them at risk for hyperglycemia, anxiety, agitation, insomnia, gastrointestinal irritation, and peptic 
ulcer disease. We attempt to avoid the potential long-term adverse effects of dexamethasone in 
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this young patient population such as obesity, avascular necrosis of the hip, and cataracts [21-
23].  
In the phase II study reported here, fosaprepitant combined with dexamethasone and 5HT3-RA 
was very well tolerated with minimal grade III or IV toxicities. However, the CR rate observed 
in this study appears to be significantly lower than our previous study with aprepitant. 
Fosaprepitant had a CR rate of 24.1% on this study compared to a CR rate of 42% with 
aprepitant [7]. While there may be several factors that contributed to the low CR rate, a notable 
one is that 15% of the patients were not evaluable for the primary endpoint due to incomplete 
patient logs.   
To the best of our knowledge, this is the first clinical trial evaluating fosaprepitant in patients 
receiving 5-day cisplatin-based chemotherapy regimens for GCT. The data in this small phase II 
study, in contrast to our prior phase III study, appears to indicate a significantly lower CR rate 
with the substitution of fosaprepitant for aprepitant. 
 
 
 
 
 
 
 
12 
 
 
 
 
Acknowledgement: 
 
-Funding/Support: Trial Supported by Merck & Co. Inc. 
-All authors had full access to all the data in the study and take responsibility for the integrity of 
the data and the accuracy of the data analysis. 
 
 
 
 
 
References 
1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: a cancer journal for 
clinicians 65 (1):5-29. doi:10.3322/caac.21254 
2. Einhorn LH (2002) Curing metastatic testicular cancer. Proceedings of the National Academy 
of Sciences of the United States of America 99 (7):4592-4595. doi:10.1073/pnas.072067999 
3. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and 
vomiting continue to reduce patients' quality of life after highly and moderately emetogenic 
chemotherapy despite antiemetic treatment. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 24 (27):4472-4478. doi:10.1200/jco.2006.05.6382 
4. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, 
Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced 
emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and 
dexamethasone or with dexamethasone alone. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology 19 (6):1759-1767 
5. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ 
(2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist 
and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to 
high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. 
Cancer 104 (4):864-868. doi:10.1002/cncr.21222 
6. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, 
Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 
13 
 
antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a 
multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose 
cisplatin--the Aprepitant Protocol 052 Study Group. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 21 (22):4112-4119. 
doi:10.1200/jco.2003.01.095 
7. Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, 
double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 
antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in 
patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a 
hoosier oncology group study. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 30 (32):3998-4003. doi:10.1200/jco.2011.39.5558 
8. Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, 
Evans JK, Murphy MG (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in 
healthy subjects. Journal of clinical pharmacology 47 (7):834-840. 
doi:10.1177/0091270007301800 
9. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, 
Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of 
chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, 
double-blind study protocol--EASE. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 29 (11):1495-1501. doi:10.1200/jco.2010.31.7859 
10. Herrstedt J (2002) Nausea and emesis: still an unsolved problem in cancer patients? 
Supportive care in cancer : official journal of the Multinational Association of Supportive Care 
in Cancer 10 (2):85-87. doi:10.1007/s00520-001-0339-7 
11. Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient 
perspectives. The journal of supportive oncology 5 (2 Suppl 1):5-12 
12. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, 
Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochlorperazine as an 
antiemetic in patients receiving cancer chemotherapy. The New England journal of medicine 300 
(23):1295-1297. doi:10.1056/nejm197906073002302 
13. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of Ondansetron (Gr 
38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting. New England 
Journal of Medicine 322 (12):810-816. doi:doi:10.1056/NEJM199003223221204 
14. Einhorn LH, Nagy C, Werner K, Finn AL (1990) Ondansetron: a new antiemetic for patients 
receiving cisplatin chemotherapy. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 8 (4):731-735 
15. Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P (2011) Antiemetic therapy for 
multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose 
chemotherapy with stem cell transplant: review and consensus statement. Supportive care in 
cancer : official journal of the Multinational Association of Supportive Care in Cancer 19 Suppl 
1:S1-4. doi:10.1007/s00520-010-0920-z 
16. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, 
Hainsworth JD, Haley B (1994) A randomized, double-blind comparison of intravenous 
ondansetron alone and in combination with intravenous dexamethasone in the prevention of 
high-dose cisplatin-induced emesis. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 12 (3):596-600 
14 
 
17. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De 
Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea 
and emesis after modern antiemetics. Cancer 100 (10):2261-2268. doi:10.1002/cncr.20230 
18. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, 
Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 
antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 
97 (9):2290-2300. doi:10.1002/cncr.11320 
19. Hale JJ, Mills SG, MacCoss M, Dorn CP, Finke PE, Budhu RJ, Reamer RA, Huskey SE, 
Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH, Cascieri MA, Chicchi GG, 
Kurtz MM, Sadowski S, Ber E, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, 
Hargreaves R, Metzger JM, MacIntyre DE (2000) Phosphorylated morpholine acetal human 
neurokinin-1 receptor antagonists as water-soluble prodrugs. Journal of medicinal chemistry 43 
(6):1234-1241 
20. Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K 
(2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-
induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, 
randomised, double-blind, placebo-controlled phase 3 trial. Annals of oncology : official journal 
of the European Society for Medical Oncology / ESMO 24 (4):1067-1073. 
doi:10.1093/annonc/mds541 
21. Cook AM, Dzik-Jurasz AS, Padhani AR, Norman A, Huddart RA (2001) The prevalence of 
avascular necrosis in patients treated with chemotherapy for testicular tumours. British journal of 
cancer 85 (11):1624-1626. doi:10.1054/bjoc.2001.2155 
22. Jobling AI, Augusteyn RC (2002) What causes steroid cataracts? A review of steroid-
induced posterior subcapsular cataracts. Clinical & experimental optometry 85 (2):61-75 
23. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the 
use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic 
chemotherapy. British journal of cancer 94 (7):1011-1015. doi:10.1038/sj.bjc.6603048 
 
 
 
-Conflicts of interest: 
Nabil Adra: none 
Costantine Albany: none 
Mary J. Brames: none 
Somer Case-Eads: none 
Cynthia Calley: husband works for Lilly and has Lilly stock in his retirement account. 
Ziyue Liu: none 
15 
 
Christopher A. Fausel: none 
Timothy Breen: none 
Nasser H. Hanna: received grant support from Merck for another study.  
Ralph J. Hauke: none 
Joel Picus: none 
Lawrence H. Einhorn: none 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Percentage of complete response (CR) in acute, delayed, and overall phase  
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Figure 2. Percentage of patients with emetic episodes on days 1 through 8 
 
 
 
 
Figure 3. Median VAS (visual analog scale) score on days 1 through 8 
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Table 1: Study Drug Schedule 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Days 6–8 
 
Dexamethasone 20 mg 
PO 
Dexamethasone 
20 mg PO 
Fosaprepitant 
150 mg IV  - 
Fosaprepitant 
150 mg IV 
Dexamethasone 
4 mg PO BID 
 
Palonosetron 0.25 mg 
IV   
Palonosetron 
0.25 mg IV -  
Palonosetron 
0.25 mg IV   
 
*Alternatively, ondansetron 8mg PO BID can be utilized on days 1 to 5 if palonosetron is not available.  
Abbreviations: PO, orally; IV, intravenous; BID, twice daily 
 
Table 2. Patient and Treatment Characteristics 
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 All patients (n=64) Evaluable Patients (n=54) 
 Median Range Median Range 
Age 33 15-66 33 15-66 
     
 n % n % 
Sex     
Male 64 100.0 54 100.0 
Race     
Caucasian 64 100.0 54 100.0 
Ethnicity     
Non-Hispanic 61 95.3 51 94.4 
Hispanic 3 4.7 3 5.6 
ECOG PS     
0 59 92.2 51 94.4 
1 4 6.2 2 3.7 
2 1 1.6 1 1.9 
Stage     
I 27 42.2 23 42.6 
II 24 37.5 21 38.9 
III 11 17.2 9 16.7 
IS 1 1.6 1 1.9 
Unknown 1 1.6 0 0.0 
Prior Chemotherapy     
Yes 5 7.8 4 7.4 
No 59 92.2 50 92.6 
Chemotherapy Regimen     
BEP 51 79.7 43 79.6 
EP 10 15.6 8 14.8 
VeIP 2 3.1 2 3.7 
Cisplatin/Epirubicin 1 1.6 1 1.9 
 
BEP=bleomycin, etoposide, cisplatin; EP=etoposide, cisplatin; VeIP=vinblastine, ifosfamide, cisplatin 
 
